Zoledronate Therapy in Osteogenesis Imperfecta: Perspectives in Indonesia Tertiary Hospital
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Osteogenesis imperfecta (OI) is a rare disease with an estimated incidence of between 1/25,000 and 1/10,000 globally. The main treatment for OI is the administration of bisphosphonate drugs. Research on clinical, radiographic, and biochemical markers to monitor patients with OI treated with zoledronate can be challenging in countries in which patients have limited national health insurance. We aimed to examine patients with OI treated in Indonesia with a minimum follow-up period of 2 years. Methods: An observational study was conducted of all patients with OI treated with zoledronate between 2021 and 2023 at a tertiary hospital in Indonesia. We evaluated the paediatric quality of life (PedsQL), bone mineral density (BMD), and alkaline phosphatase (ALP) level before and after zoledronate treatment. To monitor safety, serum creatinine and calcium levels were also measured. Results: Eleven boys (55%) and nine girls (45%), with an average age of 6.9 years (range, 4–17 years), were included. After 2 years of zoledronate treatment, the total PedsQL score increased from 66.7 to 76.9 (P=0.0001) and the mean lumbar and total body BMD increased from 0.467 and 0.501 to 0.599 g/cm2, and 0.626 g/ cm2 (P=0.001), respectively. The ALP level decreased from 310.6 to 186.4 mg/mL (P=0.0001). Neither serum creatinine (P=0.586) nor calcium (P=0.53) levels changed from the pre-treatment to 2 years post-treatment time points. Conclusions: Zoledronate was safe and effective for the treatment of OI. There were significant improvements in the quality of life and BMD in patients with OI. The ALP level decreased, but serum creatinine and calcium levels were not affected by zoledronate.
Abstract
Background: Osteogenesis imperfecta (OI) is a rare disease with an estimated incidence of between 1/25,000 and 1/10,000 globally. The main treatment for OI is the administration of bisphosphonate drugs. Research on clinical, radiographic, and biochemical markers to monitor patients with OI treated with zoledronate can be challenging in countries in which patients have limited national health insurance. We aimed to examine patients with OI treated in Indonesia with a minimum follow-up period of 2 years. Methods: An observational study was conducted of all patients with OI treated with zoledronate between 2021 and 2023 at a tertiary hospital in Indonesia. We evaluated the paediatric quality of life (PedsQL), bone mineral density (BMD), and alkaline phosphatase (ALP) level before and after zoledronate treatment. To monitor safety, serum creatinine and calcium levels were also measured. Results: Eleven boys (55%) and nine girls (45%), with an average age of 6.9 years (range, 4–17 years), were included. After 2 years of zoledronate treatment, the total PedsQL score increased from 66.7 to 76.9 (P=0.0001) and the mean lumbar and total body BMD increased from 0.467 and 0.501 to 0.599 g/cm2, and 0.626 g/ cm2 (P=0.001), respectively. The ALP level decreased from 310.6 to 186.4 mg/mL (P=0.0001). Neither serum creatinine (P=0.586) nor calcium (P=0.53) levels changed from the pre-treatment to 2 years post-treatment time points. Conclusions: Zoledronate was safe and effective for the treatment of OI. There were significant improvements in the quality of life and BMD in patients with OI. The ALP level decreased, but serum creatinine and calcium levels were not affected by zoledronate.
참고문헌 (23)
- Alharbi SA, "A systematic overview of osteogenesis imperfecta", Mol Biol, 5, pp.1000150~ (2016)[DOI]
- Marini JC, "Osteogenesis imperfecta", Nat Rev Dis Primers, 3, pp.17052~ (2017)[DOI]
- Folkestad L, "Mortality and morbidity in patients with osteogenesis imperfecta in Denmark", Dan Med J, 65, pp.B5454~ (2018)
- Thomas IH, "Advances in the classification and treatment of osteogenesis imperfecta", Curr Osteoporos Rep, 14, pp.1~9 (2016)[DOI]
- Palomo T, "Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta : Skeletal findings during follow up throughout the growing years", J Bone Miner Res, 30, pp.2150~2157 (2015)[DOI]
- Xu XJ, "The clinical characteristics and efficacy of bisphosphonates in audlt patients with osteogenesis impergecta", Endocr Pract, 22, pp.1267~1276 (2016)[DOI]
- Deeks ED, "Zoledronic acid : A review of its use in the treatment of osteoporosis", Drugs Aging, 25, pp.963~986 (2008)[DOI]
- Panigrahi I, "Response to zolendronic acid in children with type III osteogenesis imperfecta", J Bone Miner Metab, 28, pp.451~455 (2010)[DOI]
- Kumar A, "Zoledronic acid treatment in infants and toddlers with osteogenesis imperfecta is safe and effective : A tertiary care centre experience", Indian J Endocrinol Metab, 27, pp.255~259 (2023)[DOI]
- Ralston SH, "Management of osteogenesis imperfecta", Front Endocrinol(Lausanne), 10, pp.924~ (2019)[DOI]
- Otaify GA, "Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome : A 2-year prospective observational study", Osteoporos Int, 27, pp.81~92 (2016)[DOI]
- Li LJ, "Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta", Bone, 127, pp.164~171 (2019)[DOI]
- Fano V, "Osteogenesis imperfecta : Quality of life in children", Arch Argent Pediatr, 111, pp.328~331 (2013)[DOI]
- Vanz AP, "Health-related quality of life of children and adolescents with osteogenesis imperfecta : a cross-sectional study using PedsQL™", BMC Pediatr, 18, pp.95~ (2018)[DOI]
- Tsimicalis A, "Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle", Eur J Pediatr, 177, pp.891~902 (2018)[DOI]
- Nijhuis W, "Fractures in osteogenesis imperfecta : Pathogenesis, treatment, rehabilitation and prevention", Children(Basel), 9, pp.268~ (2022)[DOI]
- Gadelha APR, "Insights about the structure of farnesyl diphosphate synthase(FPPS)and the activity of bisphosphonates on the proliferation and ultrastructure of Leishmania and Giardia", Parasit Vectors, 13, pp.168~ (2020)[DOI]
- Wang B, "How zoledronic acid improves osteoporosis by acting on osteoclasts", Front Pharmacol, 13, pp.961941~ (2022)[DOI]
- Senthilnathan S, "Two doses of pamidronate in infants with osteogenesis imperfecta", Arch Dis Child, 93, pp.398~400 (2008)[DOI]
- Sakai A, "Efficacy of combined treatment with alendronate(ALN)and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis", Osteoporos Int, 26, pp.1193~1202 (2015)[DOI]
- Lv F, "Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta : A 2-year clinical study", Endocr Pract, 24, pp.179~188 (2018)[DOI]
- Saraff V, "Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis", Arch Dis Child, 103, pp.92~94 (2018)[DOI]
- Riaz M, "Safety and efficacy of zoledronic acid in children with osteogenesis imperfecta", J Coll Physicians Surg Pak, 32, pp.1165~1169 (2022)[DOI]